Semax: What Lakeland Readers Should Know

Semax is a lab-made peptide sold in Russia as nose drops and promoted in the U.S. for focus, memory and brain health. This page explains what FDA’s 2026 review found and where semax stands legally. It is general information, not advice for your situation.

What it is and how it works

Semax is a chain of seven amino acids. It is based on a fragment of ACTH, a pituitary hormone, but it lacks ACTH’s hormone effects. Its last three amino acids are thought to help it resist breakdown. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow.¹

In rodents, FDA says semax has many effects “through poorly understood mechanisms,” including on nerve protection, blood clotting, pain and mood. These are animal findings.¹

What the research shows (and where evidence is weak)

FDA reviewed semax in 2026 for stroke-related brain injury (including “nootropic,” or brain-boosting, claims), migraine and a facial nerve pain called trigeminal neuralgia. It found “insufficient evidence” for all three. ADHD was not reviewed because FDA found no supporting studies.¹

• Migraine and nerve pain. In a small 1996 study with no comparison group, a single dose stopped headache in 4 of 12 people with migraine. It did not change pain in 16 people with typical trigeminal neuralgia.¹
• Stroke. Russian studies, available in English only as summaries, report faster recovery. One compared 30 semax patients with 80 patients on usual care, without saying how they were assigned.² Another studied 110 patients after stroke.³ FDA excluded them for lack of English translations.¹
• ALS. In an open-label study of 27 people with motor neuron disease (ALS), semax did not slow the disease, though quality-of-life scores improved.⁴
• Developer involvement. One of semax’s developers co-authored the 1997 stroke study and the ALS study.²⁴

Most studies are small, lack proper control groups and are in Russian. All human studies used nasal drops.¹

FDA and regulatory status

Semax is registered in Russia as a prescription nose drop. A Russian drug reference lists it as a nootropic, with uses including memory problems linked to blood-vessel disease and recovery after stroke (registration dated March 26, 2025).⁵ Approval in Russia does not mean it has met U.S. or European standards.

In the U.S., semax is not FDA-approved and is not part of any approved drug.¹ It was once on FDA’s “Category 2” list of compounding ingredients with possible significant safety risks. By April 22, 2026, the nominations had been withdrawn; FDA still lists its safety concerns.⁶ In May 2026, FDA’s reviewers recommended against adding semax to the list of ingredients pharmacies may use.¹

An FDA advisory committee narrowly voted in July 2026 to recommend adding semax. The vote was reported as 8–5 with 1 abstention.⁷ FDA’s own reviewers had recommended against it, and the vote is not binding. As of November 2026, FDA had posted no minutes or final decision.⁸

The 2026 HHS draft policy. As of November 13, 2026, HHS has published a draft, non-binding policy saying it does not intend to take enforcement action against licensed pharmacies compounding certain peptides in certain forms. This is not FDA approval, and FDA has not added these peptides to its official list.⁹ According to law-firm summaries of the draft, semax is one of six peptides it covers, for nasal use only, with conditions such as a patient-specific prescription.¹⁰ The comment period was set to close at the end of November 13, 2026.¹¹ As of November 13, 2026, a final policy had not been published. Check the Federal Register notice for updates.⁹

Athletes should check semax’s status with their anti-doping organization or on WADA’s Prohibited List.¹²

See our guides to compounded vs. FDA-approved peptides and whether peptides are legal in Florida.

Common side effects and safety

• Little data. Most studies did not report side effects. There are no human data on how the body absorbs or clears semax, and none for injections.¹
• Bleeding. FDA noted possible blood-thinning effects, which could raise bleeding risk with other blood thinners.¹
• Abuse potential. In mice, semax boosted a brain dopamine response to amphetamine, a pattern seen with drugs of abuse. This has not been studied in people.¹
• A U.S. report. FDA found one report of eye pain and burning, with a hospital stay, after nose drops bought online.¹
• Russian label. It lists mild nasal irritation with long use. It says not to use with anxiety disorders, a history of seizures, acute psychosis, in pregnancy or breastfeeding, or in children under 7.⁵

Typical cost range

There is no FDA-approved product, and this research found no reliable U.S. price data. Ask any provider for a written price breakdown before you start.

Questions to ask a provider

• What evidence supports semax for my goal, and was it the nasal form?
• Do I take blood thinners or have a seizure or anxiety history that matters here?
• Where is the product made, and how does the HHS draft policy apply to it?

See the anti-aging goal page and our research chemical peptide risks guide.